Cell therapies have made significant improvements so far in 2023
WEST WARWICK, Rhode Island
So far in 2023:
1 cell therapy BLA approved by the FDA (1st expanded hematopoeitic stem cell product, 1st manufactured umbilical cord blood services product.
4 advanced therapies BLA submissions:
First Iovance (1st TIL cell therapy), then Adaptimmune (1st engineered TCR cell therapy), then 1st BLA submission for a CRISPR-based therapy, and now a fourth BLA submission less than a month later by bluebird bio for their gene modified HSC cell therapy. If approved that would make 3 commercial advanced therapies in one company which must be a record.
A record-setting year to-date for cell and gene therapies!